<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01363531</url>
  </required_header>
  <id_info>
    <org_study_id>PDA study</org_study_id>
    <nct_id>NCT01363531</nct_id>
  </id_info>
  <brief_title>Clinical Trial for the Assessment of Delayed Antibiotic Treatment Strategies</brief_title>
  <acronym>PDA</acronym>
  <official_title>Clinical Trial for the Assessment of Delayed Antibiotic Treatment Strategies in the Non-complicated Acute Respiratory Tract Infections in General Practice</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fundaci贸 Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fundaci贸 Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The general hypothesis is that delayed antibiotic treatment strategies present similar&#xD;
      effectiveness, when compared with non-prescription of antibiotics or the prescription of&#xD;
      antibiotics, in the non-complicated acute respiratory tract infections.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The aim of the PDA study is to assess the efficacy and safety of different delayed antibiotic&#xD;
      prescribing strategies, compared to direct antibiotic treatment and no antibiotic treatment,&#xD;
      for the treatment of non-complicated acute respiratory infections, in terms of symptoms&#xD;
      duration and severity. Moreover, antibiotic consumption, patient satisfaction, efficacy&#xD;
      perception and number of medical visits will be also assessed for each therapeutic strategy.&#xD;
&#xD;
      The PDA is a multicentric study, parallel, randomised controlled trial to compare four&#xD;
      antibiotic prescribing strategies in the non-complicated acute respiratory tract infections.&#xD;
      The trial will include acute pharyngitis and/or acute tonsillitis, rhinosinusitis, acute&#xD;
      bronchitis and acute exacerbation of chronic obstructive pulmonary disease with (mild to&#xD;
      moderate) in adults. The expected number of patients to be included in this trial is 600.&#xD;
      Therapeutic strategies include: direct antibiotic treatment, no antibiotic treatment, and two&#xD;
      delayed antibiotic prescribing strategies (prescription given to patient with advice to use a&#xD;
      course of antibiotics if needed in case of worsening of symptoms or not improving, and&#xD;
      prescription left at the reception of the primary care center 3 days after the first medical&#xD;
      visit). Follow-up period will be one month. The primary outcome will be symptom duration and&#xD;
      severity. Other outcomes included will be use of antibiotics, patient satisfaction,&#xD;
      perception of antibiotic efficacy, complications, and number of medical visits.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>December 2009</start_date>
  <completion_date type="Actual">August 2012</completion_date>
  <primary_completion_date type="Actual">August 2012</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Duration and severity of symptoms.</measure>
    <time_frame>30 days</time_frame>
    <description>Patients completed a diary of symptoms.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Antibiotic consumption at 30 days.</measure>
    <time_frame>30 days</time_frame>
    <description>Self-reported by the patients and checked at the Regional Pharmacy's Units.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient satisfaction</measure>
    <time_frame>30 days</time_frame>
    <description>Likert scale</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patients' belief in the efficacy of antibiotics</measure>
    <time_frame>30 days</time_frame>
    <description>Likert scale.</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">405</enrollment>
  <condition>Pharyngitis</condition>
  <condition>Acute Tonsillitis</condition>
  <condition>Rhinosinusitis</condition>
  <condition>Acute Bronchitis</condition>
  <condition>Chronic Obstructive Pulmonary Disease</condition>
  <arm_group>
    <arm_group_label>Direct antibiotic treatment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The doctor gives to patient an antibiotic prescription for his respiratory infection, which he should start immediately.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>No antibiotic treatment</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>The doctor doesn't give to patient an antibiotic prescription for his respiratory infection.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Delayed antibiotic prescription 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The doctor gives to patient an antibiotic prescription for his respiratory infection with the advice to use it if needed, in case of worsening of symptoms or not improving.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Delayed antibiotic prescription 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The doctor leaves the antibiotic prescription, for the respiratory infection of the patient, at the reception of the primary care center 3 days after the first medical visit. This prescription can be collected by patient if he needed, in case of worsening of symptoms or not improving.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Antibiotic prescription strategies</intervention_name>
    <description>The patients enrolled will be randomized between four treatment strategies or arms. Patients randomized to delayed treatment arms or direct treatment, doctors can choose the antibiotic that they consider appropriate depending on such local resistance or practice.</description>
    <arm_group_label>Delayed antibiotic prescription 1</arm_group_label>
    <arm_group_label>Delayed antibiotic prescription 2</arm_group_label>
    <arm_group_label>Direct antibiotic treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        General Inclusion Criteria:&#xD;
&#xD;
        In this study can be enrolled adult patients with non-complicated acute respiratory tract&#xD;
        infections, including pharyngitis and/or tonsillitis, rhinosinusitis, acute bronchitis and&#xD;
        exacerbations of chronic obstructive pulmonary disease mild to moderate. The doctors&#xD;
        include patients with these infections if they have reasonable doubts if the patients&#xD;
        should treat with antibiotics&#xD;
&#xD;
        General Exclusion Criteria:&#xD;
&#xD;
          -  Patients have participated in the PDA previously.&#xD;
&#xD;
          -  Patients are severely affected or patients has been felt severely affected for a week&#xD;
             (all time)&#xD;
&#xD;
          -  Patients with symptoms and signs suggestive of serious illness or severely affected&#xD;
             and/or complications (particularly pneumonia, mastoiditis, peritonsillar abscess,&#xD;
             peritonsillar cellulitis, intraorbital or intracranial complications).&#xD;
&#xD;
          -  Patients at high risk of serious complications due to prior comorbidity. This includes&#xD;
             significant heart disease, lung, kidney, liver or neuromuscular, immunosuppression,&#xD;
             cystic fibrosis.&#xD;
&#xD;
          -  If the patient is over 65 years with acute cough and two or more of the following&#xD;
             criteria or more than 80 years with acute cough and one or more of the following&#xD;
             criteria:&#xD;
&#xD;
          -  Hospitalization in the previous year&#xD;
&#xD;
          -  Diabetes Type I or II&#xD;
&#xD;
          -  History of heart failure&#xD;
&#xD;
          -  Current use of oral corticosteroids.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Pablo Alonso Coello, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fundaci贸 Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Fundaci贸 Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau</name>
      <address>
        <city>Barcelona</city>
        <zip>08041</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>March 2015</verification_date>
  <study_first_submitted>May 18, 2011</study_first_submitted>
  <study_first_submitted_qc>May 30, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 1, 2011</study_first_posted>
  <last_update_submitted>August 26, 2015</last_update_submitted>
  <last_update_submitted_qc>August 26, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 27, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Prescription</keyword>
  <keyword>Antibiotic</keyword>
  <keyword>Acute respiratory infections</keyword>
  <keyword>Satisfaction</keyword>
  <keyword>Perception</keyword>
  <keyword>Pharyngitis and/or acute tonsillitis</keyword>
  <keyword>Rhinosinusitis</keyword>
  <keyword>Acute bronchitis</keyword>
  <keyword>Acute exacerbation of chronic obstructive pulmonary disease (mild to moderate)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Bronchitis</mesh_term>
    <mesh_term>Pharyngitis</mesh_term>
    <mesh_term>Tonsillitis</mesh_term>
    <mesh_term>Lung Diseases</mesh_term>
    <mesh_term>Lung Diseases, Obstructive</mesh_term>
    <mesh_term>Pulmonary Disease, Chronic Obstructive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anti-Bacterial Agents</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

